NDA 017697 · Bracco
Kinevac
Sincalide · Intravenous · Cholecystokinin Analog
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Oct 17, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1976
Jul 21, 1976
Approved uses
2
Original approval plus efficacy supplements
Registered trials
7
1 Phase 3, 0 recruiting
FAERS reports
153
38 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 26, 2024.
Sincalide for Injection is indicated in adults to: to stimulate gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol, bile salts, phospholipids, and crystals; to stimulate pancreatic secretion in combination with secretin prior to obtaining a duodenal aspirate for analysis of enzyme activity, composition, and cytology; to accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract. Sincalide for Injection is a cholecystokinin (CCK) analog indicated in adults to: stimulate gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol, bile salts, phospholipids, and crystals. ( 1 ) stimulate pancreatic secretion in combination with secretin prior to obtaining a duodenal aspirate for analysis of enzyme activity, composition, and cytology. ( 1 ) accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract. ( 1 )
Mechanism: When injected intravenously, sincalide stimulates gallbladder contraction and reduction in size. The evacuation of bile that results is similar to that which occurs physiologically in response to endogenous cholecystokinin. Sincalide also stimulates pancreatic secretion and intestinal motility causing pyloric contraction and slows gastric emptying. Concurrent administration of sincalide with secretin increases both the volume of pancreatic secretion and the out-put of bicarbonate and enzymes. This combined effect of secretin and sincalide permits the assessment of specific pancreatic function...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 25, 1986 Supplement 5 · Efficacy
- Jul 21, 1976 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
- KINEVAC · SINCALIDE 0.005MG/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Sincalide" as an intervention, any sponsor and status, largest first.
- Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated CholestasisPivotal-lookingCompleted
University of MichiganAcademic, hospital or other
NCT00004414 · 252 participants · Start Sep 1997
Drug: sincalide · For: Cholestasis
Sites: Baltimore, Maryland; Ann Arbor, Michigan; Rochester, New York · 6 sites in all
Temple UniversityAcademic, hospital or other
NCT00685477 · 60 participants · Start May 2008 · Primary completion May 2009
Drug: Experimental Sequence ABC; Experimental Sequence ACB and 4 more · For: Healthy
Sites: Philadelphia, Pennsylvania
- Thyroid Hormones Homeostasis and Energy Metabolism Changes During Stimulation of Endogenously Secreted Bile Acids (BAs)Pivotal-lookingCompleted
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT00706381 · 31 participants · Start Jun 23, 2008 · Primary completion Aug 21, 2012
Drug: Sincalide; Ursodiol and 1 more · For: Healthy Volunteers
Sites: Bethesda, Maryland
GlaxoSmithKlineGSK (GSK)
NCT02496221 · 20 participants · Start Jun 11, 2015 · Primary completion Oct 13, 2015
Drug: Albiglutide 50 mg; Placebo and 1 more · For: Diabetes Mellitus, Type 2
Sites: Baltimore, Maryland
University Medicine GreifswaldAcademic, hospital or other
NCT02507167 · 19 participants · Start Nov 2012 · Primary completion Jul 2013
Drug: Rifampin · For: Gastrointestinal Hormones
Sites: Greifswald, Germany
Filip Krag KnopAcademic, hospital or other
NCT01656057 · 10 participants · Start Jul 2012 · Primary completion Oct 2013
Drug: Acetaminophen; Metformin and 1 more · For: To Assess the Impact of Bile Acids on Human Glukagon-like-peptide-1 Secretion
Sites: Copenhagen, Hellerup, Denmark
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT04567667 · 9 participants · Start Oct 15, 2020 · Primary completion Apr 11, 2021
Drug: [14C] BMS-986278; Kinevac® · For: Healthy Volunteers
Sites: Madison, Wisconsin
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective38
- drug effect decreased35
- multiple use of single-use product29
- no adverse event24
- nausea13
- product quality issue11
- therapeutic product effect decreased11
- diarrhoea8
- gallbladder disorder8
- pain8
- abdominal pain7
- chills7
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 2 |
| 2007 | 3 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 4 |
| 2012 | 2 |
| 2013 | 12 |
| 2014 | 37 |
| 2015 | 14 |
| 2016 | 20 |
| 2017 | 7 |
| 2018 | 10 |
| 2019 | 20 |
| 2020 | 4 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 6 |
| 2026 | 3 |
Recalls
1 FDA enforcement reports for this application.
Apr 13, 2022 · Class II · Terminated
cGMP deviations: Temperature abuse
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Kinevac* (Sincalide*) · HCPCS J2805
2024 spending
$424K
Beneficiaries
3,409
3,417 claims
Per beneficiary
$124
2024 ASP limit $132.25 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $584,163 |
| 2021 | $484,209 |
| 2022 | $372,661 |
| 2023 | $485,145 |
| 2024 | $423,518 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Acalculous biliary pain: cholecystectomy alleviates symptoms in patients with abnormal cholescintigraphy.
Yap L, Wycherley AG, Morphett AD, et al. · Gastroenterology 1991 · Clinical Trial, Randomized Controlled Trial
- Oral Cholecystagogue Cholescintigraphy: A Systematic Review of Fatty Meal Options.
Fotos JS, Tulchinsky M · Clin Nucl Med 2015 · Systematic Review
- Cholecystokinin cholescintigraphy: methodology and normal values using a lactose-free fatty-meal food supplement.
Ziessman HA, Jones DA, Muenz LR, et al. · J Nucl Med 2003 · Clinical Trial, Validation Study
- Studies of gallbladder contraction using intramuscular sincalide.
Rosenquist CJ, Barcia TC · Radiology 1983 · Clinical Trial, Controlled Clinical Trial
- Sincalide-stimulated cholescintigraphy: a multicenter investigation to determine optimal infusion methodology and gallbladder ejection fraction normal values.
Ziessman HA, Tulchinsky M, Lavely WC, et al. · J Nucl Med 2010 · Clinical Trial, Multicenter Study
- Failure of beta-adrenergic stimulation to affect cholecystokinin-stimulated sigmoid motility in man.
Lyrenäs E, Abrahamsson H, Dotevall G · Scand J Gastroenterol 1985 · Clinical Trial, Randomized Controlled Trial
Sponsor: Bracco
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.